Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 53rd Annual Meeting & Exposition of the American Society of Hematology
Targeted Therapy for Complement Inhibition: Preventing Life-threatening Thrombosis
San Diego, California / December 10-13, 2011
San Diego - Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are 2 diseases driven by the complement system that respond to a monoclonal antibody (MAb) that binds to the human C5 complement protein and...
MEDICAL FRONTIERS - 53rd Annual Meeting & Exposition of the American Society of Hematology
Targeted Therapies Providing Major Clinical Advances in Myeloproliferative Neoplasms
San Diego, California / December 10-13, 2011
San Diego - Progress in understanding the molecular pathophysiology of myeloproliferative neoplasms (MPNs) is generating new therapies that appear capable of inhibiting key steps in the disease process. In myelofibrosis, polycythemia vera...
PHYSICIAN PERSPECTIVE - Viewpoint based on presentations at the 53rd Annual Meeting & Exposition of the American Society of Hematology
Maintenance Therapy as an Emerging Standard for Improving Survival in Multiple Myeloma
San Diego, California / December 10-13, 2011
Reviewed and edited by: Donna E. Reece, BA, MD, FRCPCDirector, Program for Multiple Myeloma and Related Diseases Princess Margaret Hospital Associate Professor of Medicine University of Toronto Toronto, Ontario Introduction One of...
PRIORITY PRESS - 53rd Annual Meeting & Exposition of the American Society of Hematology
Simplifying Monitoring with Oral Anticoagulants
San Diego, California / December 10-13, 2011
San Diego - The choice of oral anticoagulants has expanded with the introduction of agents that do not require therapeutic drug monitoring. In new comparative data with warfarin, these agents are continuing to demonstrate advantages in a...
MEDICAL FRONTIERS - Canadian Association of Nephrology Nurses and Technologists (CANNT) 2011
Partnering with Patients on Hemodialysis: Nursing Support, Advocacy and Skills
Calgary, Alberta / October 20-22, 2011
Chief Medical Editor: Dr. Léna Coïc, Montréal, Quebec A major preoccupation for hemodialysis (HD) patients is the many decisions they must make throughout the trajectory of their care. Here at CANNT, HD nurse...
PRIORITY PRESS - XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH)/ 57th Annual Scientific and Standardization Committee (SSC) Meeting
Advances in the Treatment of Hemophilia B
Kyoto, Japan / July 23-28, 2011
Kyoto - Hemophilia B is the inherited disorder characterized by a deficiency in blood coagulation factor IX (FIX). Current treatment for hemophilia B is plasma-derived FIX or recombinant FIX (rFIX). Although rFIX avoids the risk of viral...
PRIORITY PRESS - 17th Congress of the International Liver Transplantation Society (ILTS)
Simplifying Immunosuppression for Liver Transplant Recipients: A Lifelong Commitment to Optimize Patient and Graft Survival
Valencia, Spain / June 22-25, 2011
Valencia - Following organ transplantation, anti-rejection drug efficacy is critical to optimal patient and graft survival but so, too, are tolerability and ease of administration. The calcineurin inhibitors (CNIs) have a long track record...
PRIORITY PRESS - 16th Congress of the European Hematology Association (EHA)
Improving Response Rates and Duration in Patients with Multiple Myeloma
London, UK / June 9-12, 2011
London - Initially studied in the treatment of multiple myeloma patients in relapsed and refractory settings, proteasome inhibitor-based regimens have now been shown to improve outcomes in transplant-eligible and -ineligible patients with...
MEDICAL FRONTIERS - 16th Congress of the European Hematology Association (EHA)
Improving Responses to First-line Treatment in Chronic Myeloid Leukemia
London, United Kingdom / June 9-12, 2011
London - With the introduction of the first tyrosine kinase inhibitor (TKI) 10 years ago, treatment of chronic myeloid leukemia (CML) was revolutionized. Imatinib became the standard of care and in follow-up analysis of clinical trials it...